OBJECTIVE: We investigated factors associated with distant recurrence, disease-free survival (DFS), and overall survival (OS) following R0 lobectomy for pathologic node-negative (pN0) lung adenocarcinoma. METHODS: We performed a retrospective analysis of a prospectively maintained database of patients with pT1-3N0M0 non-small cell lung cancer. Exclusion criteria included metachronous lung cancer, sublobar/incomplete resection, nonadenocarcinoma histology, and induction/adjuvant therapy. The primary outcome was distant recurrence; secondary outcomes were DFS and OS. Associations between variables and outcomes were assessed by Fine-Gray competing-risk regression for distant recurrence and Cox proportional hazard models for DFS and OS. RESULTS: Of 2392 patients identified with pT1-3N0M0 lung adenocarcinoma, 893 met the inclusion criteria. Median follow-up was 35.0 months (range, 0.1-202 months). Thirteen percent of patients developed recurrence (n = 115), of which 86% (n = 99) were distant. The 5-year cumulative incidence of distant recurrence was 14% (95% confidence interval [CI], 11%-17%). On multivariable analysis, pT2a (hazard ratio [HR], 2.84; 95% CI, 1.56-5.16; P = .001) and pT2b/3 (HR, 6.53; 95% CI, 3.17-13.5; P < .001) tumors were associated with distant recurrence. Recent surgery was associated with decreased distant recurrence (HR, 0.43; 95% CI, 0.20-0.91; P = .028), and lymphovascular invasion was strongly associated with distant recurrence (HR, 1.62; 95% CI, 1.00-2.63; P = .05). DFS was independently associated with pT stage (P < .001) and lymphovascular invasion (P = .004). CONCLUSIONS: In patients undergoing R0 lobectomy with pN0 lung adenocarcinoma, pT stage and lymphovascular invasion were associated with distant recurrence and decreased DFS. These observations support the inclusion of these patients in future clinical trials investigating adjuvant targeted and immunotherapies.
OBJECTIVE: We investigated factors associated with distant recurrence, disease-free survival (DFS), and overall survival (OS) following R0 lobectomy for pathologic node-negative (pN0) lung adenocarcinoma. METHODS: We performed a retrospective analysis of a prospectively maintained database of patients with pT1-3N0M0 non-small cell lung cancer. Exclusion criteria included metachronous lung cancer, sublobar/incomplete resection, nonadenocarcinoma histology, and induction/adjuvant therapy. The primary outcome was distant recurrence; secondary outcomes were DFS and OS. Associations between variables and outcomes were assessed by Fine-Gray competing-risk regression for distant recurrence and Cox proportional hazard models for DFS and OS. RESULTS: Of 2392 patients identified with pT1-3N0M0 lung adenocarcinoma, 893 met the inclusion criteria. Median follow-up was 35.0 months (range, 0.1-202 months). Thirteen percent of patients developed recurrence (n = 115), of which 86% (n = 99) were distant. The 5-year cumulative incidence of distant recurrence was 14% (95% confidence interval [CI], 11%-17%). On multivariable analysis, pT2a (hazard ratio [HR], 2.84; 95% CI, 1.56-5.16; P = .001) and pT2b/3 (HR, 6.53; 95% CI, 3.17-13.5; P < .001) tumors were associated with distant recurrence. Recent surgery was associated with decreased distant recurrence (HR, 0.43; 95% CI, 0.20-0.91; P = .028), and lymphovascular invasion was strongly associated with distant recurrence (HR, 1.62; 95% CI, 1.00-2.63; P = .05). DFS was independently associated with pT stage (P < .001) and lymphovascular invasion (P = .004). CONCLUSIONS: In patients undergoing R0 lobectomy with pN0 lung adenocarcinoma, pT stage and lymphovascular invasion were associated with distant recurrence and decreased DFS. These observations support the inclusion of these patients in future clinical trials investigating adjuvant targeted and immunotherapies.
Authors: Benjamin Izar; Haiyu Zhou; Rebecca S Heist; Christopher G Azzoli; Alona Muzikansky; Emily E F Scribner; Lindsay A Bernardo; Dora Dias-Santagata; Anthony J Iafrate; Michael Lanuti Journal: J Thorac Oncol Date: 2014-09 Impact factor: 15.609
Authors: Jacquelyn G Hancock; Joshua E Rosen; Alberto Antonicelli; Amy Moreno; Anthony W Kim; Frank C Detterbeck; Daniel J Boffa Journal: Ann Thorac Surg Date: 2014-12-17 Impact factor: 4.330
Authors: Nathan M Mollberg; Carrie Bennette; Eric Howell; Leah Backhus; Beth Devine; Mark K Ferguson Journal: Ann Thorac Surg Date: 2014-01-11 Impact factor: 4.330
Authors: Jian Zhou; Francisco Sanchez-Vega; Raul Caso; Kay See Tan; Whitney S Brandt; Gregory D Jones; Shi Yan; Prasad S Adusumilli; Matthew Bott; James Huang; James M Isbell; Smita Sihag; Daniela Molena; Valerie W Rusch; Walid K Chatila; Natasha Rekhtman; Fan Yang; Marc Ladanyi; David B Solit; Michael F Berger; Nikolaus Schultz; David R Jones Journal: Clin Cancer Res Date: 2019-08-27 Impact factor: 12.531
Authors: Raymond U Osarogiagbon; Nicholas R Faris; Walter Stevens; Carrie Fehnel; Cheryl Houston-Harris; Philip Ojeabulu; Olawale A Akinbobola; Yu-Shen Lee; Meredith A Ray; Matthew P Smeltzer Journal: J Thorac Oncol Date: 2019-11-26 Impact factor: 15.609